Nutritional properties and osteogenic activity of enzymatic hydrolysates of proteins from the blue mussel (Mytilus edulis)

2019 ◽  
Vol 10 (12) ◽  
pp. 7745-7754 ◽  
Author(s):  
Zhe Xu ◽  
Fujunzhu Zhao ◽  
Hui Chen ◽  
Shiqi Xu ◽  
Fengjiao Fan ◽  
...  

Seafood provides a range of health benefits due to its nutritional and bioactive components. The proteins and peptides from Mytilus edulis have good bone growth promoting activities.

Genetics ◽  
2004 ◽  
Vol 166 (2) ◽  
pp. 883-894
Author(s):  
Liqin Cao ◽  
Ellen Kenchington ◽  
Eleftherios Zouros

Abstract In Mytilus, females carry predominantly maternal mitochondrial DNA (mtDNA) but males carry maternal mtDNA in their somatic tissues and paternal mtDNA in their gonads. This phenomenon, known as doubly uniparental inheritance (DUI) of mtDNA, presents a major departure from the uniparental transmission of organelle genomes. Eggs of Mytilus edulis from females that produce exclusively daughters and from females that produce mostly sons were fertilized with sperm stained with MitoTracker Green FM, allowing observation of sperm mitochondria in the embryo by epifluorescent and confocal microscopy. In embryos from females that produce only daughters, sperm mitochondria are randomly dispersed among blastomeres. In embryos from females that produce mostly sons, sperm mitochondria tend to aggregate and end up in one blastomere in the two- and four-cell stages. We postulate that the aggregate eventually ends up in the first germ cells, thus accounting for the presence of paternal mtDNA in the male gonad. This is the first evidence for different behaviors of sperm mitochondria in developing embryos that may explain the tight linkage between gender and inheritance of paternal mitochondrial DNA in species with DUI.


2021 ◽  
Vol 167 ◽  
pp. 112295
Author(s):  
Amina Khalid ◽  
Aurore Zalouk-Vergnoux ◽  
Samira Benali ◽  
Rosica Mincheva ◽  
Jean-Marie Raquez ◽  
...  
Keyword(s):  

Author(s):  
Ravi Savarirayan ◽  
Louise Tofts ◽  
Melita Irving ◽  
William R. Wilcox ◽  
Carlos A. Bacino ◽  
...  

Abstract Purpose Achondroplasia is caused by pathogenic variants in the fibroblast growth factor receptor 3 gene that lead to impaired endochondral ossification. Vosoritide, an analog of C-type natriuretic peptide, stimulates endochondral bone growth and is in development for the treatment of achondroplasia. This phase 3 extension study was conducted to document the efficacy and safety of continuous, daily vosoritide treatment in children with achondroplasia, and the two-year results are reported. Methods After completing at least six months of a baseline observational growth study, and 52 weeks in a double-blind, placebo-controlled study, participants were eligible to continue treatment in an open-label extension study, where all participants received vosoritide at a dose of 15.0 μg/kg/day. Results In children randomized to vosoritide, annualized growth velocity increased from 4.26 cm/year at baseline to 5.39 cm/year at 52 weeks and 5.52 cm/year at week 104. In children who crossed over from placebo to vosoritide in the extension study, annualized growth velocity increased from 3.81 cm/year at week 52 to 5.43 cm/year at week 104. No new adverse effects of vosoritide were detected. Conclusion Vosoritide treatment has safe and persistent growth-promoting effects in children with achondroplasia treated daily for two years.


1984 ◽  
Vol 11 (4) ◽  
pp. 253-274 ◽  
Author(s):  
A. Calabrese ◽  
J.R. MacInnes ◽  
D.A. Nelson ◽  
R.A. Greig ◽  
P.P. Yevich
Keyword(s):  

2018 ◽  
Vol 137 ◽  
pp. 638-645 ◽  
Author(s):  
Madelyn N. Woods ◽  
Margaret E. Stack ◽  
David M. Fields ◽  
Susan D. Shaw ◽  
Patricia A. Matrai
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document